SEARCH

SEARCH BY CITATION

References

  • Andersen, C.L., Jensen, J.L. & Orntoft, T.F. (2004) Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Research, 64, 52455250.
  • Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B, 57, 289300.
  • Blandino, G., Levine, A.J. & Oren, M. (1999) Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. Oncogene, 18, 477485.
  • Brosh, R. & Rotter, V. (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer, 9, 701713.
  • Bykov, V.J., Lambert, J.M., Hainaut, P. & Wiman, K.G. (2009) Mutant p53 rescue and modulation of p53 redox state. Cell Cycle, 8, 25092517.
  • Carter, A., Lin, K., Sherrington, P.D. & Pettitt, A.R. (2004) Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. British Journal of Haematology, 127, 425428.
  • Carter, A., Lin, K., Sherrington, P.D., Atherton, M., Pearson, K., Douglas, A., Burford, A., Brito-Babapulle, V., Matutes, E., Catovsky, D. & Pettitt, A.R. (2006) Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia, 20, 737740.
  • Chang, J.W., Chen, Y.C., Chen, C.Y., Chen, J.T., Chen, S.K. & Wang, Y.C. (2000) Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clinical Cancer Research, 6, 16391646.
  • Chène, P., Ory, K., Rüedi, D., Soussi, T. & Hegi, M.E. (1999) Functional analyses of a unique p53 germline mutant (Y236D) associated with a familial brain tumor syndrome. International Journal of Cancer, 82, 1722.
  • Cheok, C.F., Verma, C.S., Baselga, J. & Lane, D.P. (2010) Translating p53 into the clinic. Nature Reviews Clinical Oncology, 8, 2537.
  • Chiorazzi, N., Rai, K. & Ferrarini, M. (2005) Chronic lymphocytic leukemia. New England Journal of Medicine, 352, 804815.
  • Dicker, F., Schnittger, S., Haferlach, T., Kern, W. & Schoch, C. (2006) Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: a study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood, 108, 31523160.
  • Dicker, F., Herholz, H., Schnittger, S., Nakao, A., Patten, N., Wu, L., Kern, W., Haferlach, T. & Haferlach, C. (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia, 23, 117124.
  • Döhner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Kröber, A., Bullinger, L., Döhner, K., Bentz, M. & Lichter, P. (2000) Genomic aberrations and survival in chronic lymphocytic leukemia. New England Journal of Medicine, 343, 19101916.
  • El-Deiry, W.S., Kern, S.E., Pietenpol, J.A., Kinzler, K.W. & Vogelstein, B. (1992) Definition of a consensus binding site for p53. Nature Genetics, 1, 4549.
  • Fabris, S., Mosca, L., Todoerti, K., Cutrona, G., Lionetti, M., Intini, D., Matis, S., Colombo, M., Agnelli, L., Gentile, M., Spriano, M., Callea, V., Festini, G., Molica, S., Deliliers, G.L., Morabito, F., Ferrarini, M. & Neri, A. (2008) Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. Genes Chromosomes Cancer, 47, 781793.
  • Gandini, D., Aguiari, G.L., Cuneo, A., Piva, R., Castoldi, G.L. & del Senno, L. (1994) Novel small deletions of the p53 gene in late-stage B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 88, 881885.
  • Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., Hornik, K., Hothorn, T., Huber, W., Iacus, S., Irizarry, R., Leisch, F., Li, C., Maechler, M., Rossini, A.J., Sawitzki, G., Smith, C., Smyth, G., Tierney, L., Yang, J.Y. & Zhang, J. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biology, 5, R80.
  • Grever, M.R., Lucas, D.M., Dewald, G.W., Neuberg, D.S., Reed, J.C., Kitada, S., Flinn, I.W., Tallman, M.S., Appelbaum, F.R., Larson, R.A., Paietta, E., Jelinek, D.F., Gribben, J.G. & Byrd, J.C. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US intergroup phase III trial E2997. Journal of Clinical Oncology, 25, 799804.
  • Gyorffy, B., Molnar, B., Lage, H., Szallasi, Z. & Eklund, A.C. (2009) Evaluation of microarray preprocessing algorithms based on concordance with RT-PCR in clinical samples. PLoS ONE, 4, e5645.
  • Harvey, M., Vogel, H., Morris, D., Bradley, A., Bernstein, A. & Donehower, L.A. (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genetics, 9, 305311.
  • Haslinger, C., Schweifer, N., Stilgenbauer, S., Döhner, H., Lichter, P., Kraut, N., Stratowa, C. & Abseher, R. (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. Journal of Clinical Oncology, 22, 39373949.
  • Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J., Scherf, U. & Speed, T.P. (2003) Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Research, 31, e15.
  • Jego, N., Thomas, G. & Hamelin, R. (1993) Short direct repeats flanking deletions, and duplicating insertions in p53 gene in human cancers. Oncogene, 8, 209213.
  • Kienle, D.L., Korz, C., Hosch, B., Benner, A., Mertens, D., Habermann, A., Kröber, A., Jäger, U., Lichter, P., Döhner, H. & Stilgenbauer, S. (2005) Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. Journal of Clinical Oncology, 23, 37803792.
  • Kim, E. & Deppert, W. (2004) Transcriptional activities of mutant p53: when mutations are more than a loss. Journal of Cellular Biochemistry, 93, 878886.
  • Li, R., Sutphin, P.D., Schwartz, D., Matas, D., Almog, N., Wolkowicz, R., Goldfinger, N., Pei, H., Prokocimer, M. & Rotter, V. (1998) Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene, 16, 32693277.
  • Lin, K., Rockliffe, N., Johnson, G.G., Sherrington, P.D. & Pettitt, A.R. (2008) Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. Oncogene, 27, 24452455.
  • Liu, G., McDonnell, T.J., Montes de Oca Luna, R., Kapoor, M., Mims, B., El-Naggar, A.K. & Lozano, G. (2000) High metastatic potential in mice inheriting a targeted p53 missense mutation. Proceedings of the National Academy of Sciences of the United States of America, 97, 41744179.
  • Lu, C. & El-Deiry, W.S. (2009) Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis, 14, 597606.
  • Malcikova, J., Smardova, J., Rocnova, L., Tichy, B., Kuglik, P., Vranova, V., Cejkova, S., Svitakova, M., Skuhrova Francova, H., Brychtova, Y., Doubek, M., Brejcha, M., Klabusay, M., Mayer, J., Pospisilova, S. & Trbusek, M. (2009) Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage. Blood, 114, 53075314.
  • Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N. & Rotter, V. (2001) Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis. The EMBO Journal, 20, 41634172.
  • Meek, D.W. (2009) Tumour suppression by p53: a role for the DNA damage response? Nature Reviews Cancer, 9, 714723.
  • Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P. & Olivier, M. (2007a) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation, 28, 622629.
  • Petitjean, A., Achatz, M.I., Borresen-Dale, A.L., Hainaut, P. & Olivier, M. (2007b) TP53 mutations in Human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene, 26, 21572165.
  • Riley, T., Sontag, E., Chen, P. & Levine, A. (2008) Transcriptional control of human p53-regulated genes. Nature Reviews Molecular Cell Biology, 9, 402412.
  • Rossi, D., Cerri, M., Deambrogi, C., Sozzi, E., Cresta, S., Rasi, S., De Paoli, L., Spina, V., Gattei, V., Capello, D., Forconi, F., Lauria, F. & Gaidano, G. (2009) The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clinical Cancer Research, 15, 9951004.
  • Scian, M.J., Stagliano, K.E., Ellis, M.A., Hassan, S., Bowman, M., Miles, M.F., Deb, S.P. & Deb, S. (2004) Modulation of gene expression by tumor-derived p53 mutants. Cancer Research, 64, 74477454.
  • Scian, M.J., Stagliano, K.E., Anderson, M.A., Hassan, S., Bowman, M., Miles, M.F., Deb, S.P. & Deb, S. (2005) Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Molecular and Cellular Biology, 25, 1009710110.
  • Smyth, G.K. (2004) Linear models and empirical Bayes methods for assessing differential expression in microarray experiments. Statistical Applications in Genetics and Molecular Biology, 3, Article3.
  • Stankovic, T., Hubank, M., Cronin, D., Stewart, G.S., Fletcher, D., Bignell, C.R., Alvi, A.J., Austen, B., Weston, V.J., Fegan, C., Byrd, P.J., Moss, P.A. & Taylor, A.M. (2004) Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. Blood, 103, 291300.
  • Steele, A.J., Prentice, A.G., Hoffbrand, A.V., Yogashangary, B.C., Hart, S.M., Nacheva, E.P., Howard-Reeves, J.D., Duke, V.M., Kottaridis, P.D., Cwynarski, K., Vassilev, L.T. & Wickremasinghe, R.G. (2008) p53-mediated apoptosis of CLL cells: evidence for a transcription-independent mechanism. Blood, 112, 38273834.
  • Stilgenbauer, S., Zenz, T., Winkler, D., Bühler, A., Busch, R., Fingerle-Rowson, G., Fischer, K., Fink, A.M., Jäger, U., Böttcher, S., Kneba, M., Wenger, M., Mendila, M., Hallek, M. & Döhner, H. (2008) Genomic aberrations, VH mutation status and outcome after fludarabine and cyclophosphamide (FC) or FC plus Rituximab (FCR) in the CLL8 trial [ASH Annual Meeting Abstract]. Blood, 112, 781a.
  • Strano, S., Dell'Orso, S., Di Agostino, S., Fontemaggi, G., Sacchi, A. & Blandino, G. (2007) Mutant p53:an oncogenic transcription factor. Oncogene, 26, 22122219.
  • Tepper, C.G., Gregg, J.P., Shi, X.B., Vinall, R.L., Baron, C.A., Ryan, P.E., Desprez, P.Y., Kung, H.J. & deVere White, R.W. (2005) Profiling of gene expression changes caused by p53 gain-of-function mutant alleles in prostate cancer cells. Prostate, 65, 375389.
  • Toledo, F. & Wahl, G.M. (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Reviews Cancer, 6, 909923.
  • Vogelstein, B., Lane, D. & Levine, A.J. (2000) Surfing the p53 network. Nature, 408, 307310.
  • Wilson, C.L. & Miller, C. (2005) Simpleaffy: a BioConductor package for Affymetrix Quality Control and data analysis. Bioinformatics, 21, 36833685.
  • Yamanoshita, O., Kubota, T., Hou, J., Ping, Y.M., Zhang, X.L., Li, X.P., Li, S.S., Li, X.X., Zhu, D.C., Fukushima, Y. & Nakajima, T. (2005) DHPLC is superior to SSCP in screening p53 mutations in esophageal cancer tissues. International Journal of Cancer, 114, 7479.
  • Zache, N., Lambert, J.M., Rökaeus, N., Shen, J., Hainaut, P., Bergman, J., Wiman, K.G. & Bykov, V.J. (2008) Mutant p53 targeting by the low molecular weight compound STIMA-1. Molecular Oncology, 2, 7080.
  • Zenz, T., Krober, A., Scherer, K., Häbe, S., Bühler, A., Benner, A., Denzel, T., Winkler, D., Edelmann, J., Schwänen, C., Döhner, H. & Stilgenbauer, S. (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood, 112, 33223329.
  • Zenz, T., Hoth, P., Busch, R., Helfrich, H., Winkler, D., Bühler, A., Patten, N., Truong, S., Wu, L., Fingerle-Rowson, G., Fischer, K., Fink, A.M., Jäger, U., Böttcher, S., Kneba, M., Wenger, M.K., Mendila, M., Hallek, M., Döhner, H. & Stilgenbauer, S. (2009a) TP53 mutations and outcome after fludarabine and cyclophosphamide (FC) or FC plus rituximab (FCR) in the CLL8 Trial of the GCLLSG [ASH Annual Meeting Abstract]. Blood, 114, 1267a.
  • Zenz, T., Häbe, S., Denzel, T., Mohr, J., Winkler, D., Bühler, A., Sarno, A., Groner, S., Mertens, D., Busch, R., Hallek, M., Döhner, H. & Stilgenbauer, S. (2009b) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial. Blood, 114, 25892597.
  • Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Häbe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Döhner, H. & Stilgenbauer, S. European Research Initiative on CLL (ERIC). (2010) TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24, 20722079.